From science to patients: Opportunities and new trends in ADCs
Panel discussion summary
From science to patients: Opportunities and new trends in ADCs
Date, time and room information
May 5, 17:30-18:15, room Marriott 1+2
Moderation
| Name | Position | Institution |
|---|---|---|
| Jean Engela | CEO | NBE-Therapeutics AG |
Panelists
| Name | Position | Institution |
|---|---|---|
| Dr Carl Deutsch | CSO | NBE-Therapeutics AG |
| Dr Christian Kunz | Vice President Discovery Biology | Ridgeline Discovery |
| Dr Frédéric Levy | CSO | Debiopharm |
| Dr Jimmy Li | CEO | WuXi XDC |
| Prof Dr med Gerd Munzert | CMO | T3 Pharma |
NBE-Therapeutics AG
NBE Therapeutics, founded in 2012 and headquartered in Basel, Switzerland, is a renowned biotechnology company at the forefront of developing next-generation antibody drug conjugate (ADC) products for cancer treatment. Committed to scientific excellence and innovation, NBE Therapeutics is dedicated to revolutionizing the field of oncology therapeutics by providing precise and effective treatment options.
